Core Insights - Lexeo Therapeutics, Inc. has announced key senior leadership appointments to enhance its expertise in cardiovascular medicine and late-stage clinical development [1] - The company provided an update on its strategic partnership with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases using a novel non-viral RNA platform [1] Leadership Appointments - Dr. Narinder Bhalla has been appointed as Chief Medical Officer, bringing over 20 years of experience as an interventional cardiologist and nearly a decade in biopharma leadership [2] - Eric Adler, previously Head of Research at Lexeo, will serve as President and CEO of Myoventive, a company co-founded by Lexeo to address genetic cardiac diseases [3] - José Manuel Otero has been appointed Chief Operating Officer, transitioning from Chief Technical Officer, to further elevate performance across Lexeo's operations [4] - Dr. Hayes Dansky has joined as Vice President, Late-Stage Cardiology Development, with extensive experience in cardiovascular research and development [4] - Dr. Greg Aubert has been named Vice President, Early-Stage Cardiology Development and Translational Science, specializing in cardiovascular genetics and gene therapy [4][5] Company Mission and Pipeline - Lexeo Therapeutics is focused on reshaping heart health by developing therapies targeting the underlying genetic causes of cardiovascular diseases [6] - The company is advancing a portfolio of therapeutic candidates, including LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy [6]
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics